DownloadHi-Res Photo

Laurine Bow, PhD

Associate Professor of Surgery (Transplant)

Research & Publications
Biography

Coauthors

Selected Publications

P111 Navigating through discordant results towards a successful transplantRewinski M, Doyle P, Bow L. P111 Navigating through discordant results towards a successful transplant. Human Immunology 2023, 84: 69. DOI: 10.1016/j.humimm.2023.08.013.
Abstract 13769: AT1R Autoantibody Levels Are Elevated in Patients Who Required Immunosuppression Escalation in Immune Checkpoint Inhibitor Mediated MyocarditisAkhlaghi N, Shen M, Bow L, Miller M, Hwa J, Halene S, Baldassarre L, Kwan J. Abstract 13769: AT1R Autoantibody Levels Are Elevated in Patients Who Required Immunosuppression Escalation in Immune Checkpoint Inhibitor Mediated Myocarditis. Circulation 2022, 146: a13769-a13769. DOI: 10.1161/circ.146.suppl_1.13769.
210.15: MRNA Based Vaccines Against SARS-CoV-2 Do Not Alter cPRA in Patients Awaiting Kidney TransplantRewinski M, Doyle P, Durkin D, Vicki S, Devivo J, Caruk R, Haberman A, Palmeri D, Cyr P, Morgan G, Serrano O, Emmanuel B, Ebcioglu Z, Singh J, Kent R, Ye X, Tremaglio J, Bow L, Dar W. 210.15: MRNA Based Vaccines Against SARS-CoV-2 Do Not Alter cPRA in Patients Awaiting Kidney Transplant. Transplantation 2022, 106: s9-s10. DOI: 10.1097/01.tp.0000885248.19450.6c.
P194 What’s in your unacceptable antigen toolbox? lifecodes validation at yaleMiller M, Rivera J, Bow L. P194 What’s in your unacceptable antigen toolbox? lifecodes validation at yale. Human Immunology 2019, 80: 209. DOI: 10.1016/j.humimm.2019.07.247.
P170 Can FBS expeditiously reduce non-specific reactivity in pre-transplant heart recipients?Miller M, Warner M, Bow L. P170 Can FBS expeditiously reduce non-specific reactivity in pre-transplant heart recipients? Human Immunology 2019, 80: 192. DOI: 10.1016/j.humimm.2019.07.223.
P022 Case study: A closer look for DSA in a zero antigen mismatch kidney transplant recipientMiller M, Bow L. P022 Case study: A closer look for DSA in a zero antigen mismatch kidney transplant recipient. Human Immunology 2019, 80: 72. DOI: 10.1016/j.humimm.2019.07.074.
P020 Comprehensive HLA typing and antibody testing reaffirms an acceptable donor–recipient exchangeRewinski M, Doyle P, DeVivo J, Vicki S, Durkin D, Bow L. P020 Comprehensive HLA typing and antibody testing reaffirms an acceptable donor–recipient exchange. Human Immunology 2019, 80: 70. DOI: 10.1016/j.humimm.2019.07.072.
P018 Interpreting positive crossmatches with allele specific antibodiesRewinski M, Doyle P, DeVivo J, Vicki S, Durkin D, Bow L. P018 Interpreting positive crossmatches with allele specific antibodies. Human Immunology 2019, 80: 68. DOI: 10.1016/j.humimm.2019.07.070.
P032 Edta elucidates unexpected crossmatch resultsRewinski M, Doyle P, DeVivo J, Vicki S, Durkin D, Bow L. P032 Edta elucidates unexpected crossmatch results. Human Immunology 2018, 79: 84. DOI: 10.1016/j.humimm.2018.07.090.
P026Timing is everything – Even for DP antibodiesRewinski M, Doyle P, Bow L. P026Timing is everything – Even for DP antibodies. Human Immunology 2018, 79: 80. DOI: 10.1016/j.humimm.2018.07.084.
P039 The bumpy road to epic beaker implementationMiller M, Bow L. P039 The bumpy road to epic beaker implementation. Human Immunology 2018, 79: 88. DOI: 10.1016/j.humimm.2018.07.097.
P038 Donor specific anti-a titer for abo incompatible (ABOi) living kidney transplantationMiller M, Bow L. P038 Donor specific anti-a titer for abo incompatible (ABOi) living kidney transplantation. Human Immunology 2018, 79: 88. DOI: 10.1016/j.humimm.2018.07.096.
OR51 Correlation of class II antibody development with acute cellular rejection and fibrosis in pediatric liver transplantationBow L, Ekong U, Morotti R, Antala S, Emre S. OR51 Correlation of class II antibody development with acute cellular rejection and fibrosis in pediatric liver transplantation. Human Immunology 2017, 78: 47. DOI: 10.1016/j.humimm.2017.06.057.
P002 The consistent inconsistency in HLA antibody testing practices: a collaboration with the Banff workgroupDadhania D, Jackson A, Campbell P, Bow L, Almeshari K, Schinstock C, Cornell L, Bagnasco S, Kraus E, Cozzi E, Askar M. P002 The consistent inconsistency in HLA antibody testing practices: a collaboration with the Banff workgroup. Human Immunology 2016, 77: 41. DOI: 10.1016/j.humimm.2016.07.067.
P054 EDTA treatment of serum eliminates interference in flow cytometric crossmatchesRewinski M, Ortiz J, Alberghini T, Bow L, Devivo J, Doyle P, Michalski T. P054 EDTA treatment of serum eliminates interference in flow cytometric crossmatches. Human Immunology 2016, 77: 78. DOI: 10.1016/j.humimm.2016.07.119.
P148 Uncovering antibodies to cryptic epitopes: Use of flow cytometry crossmatch to differentiate between functional and denatured epitopesMangiola M, Lomago J, Marilyn M, Nichol L, Zern D, McGowan K, Sese D, Bow L, Zeevi A. P148 Uncovering antibodies to cryptic epitopes: Use of flow cytometry crossmatch to differentiate between functional and denatured epitopes. Human Immunology 2016, 77: 145. DOI: 10.1016/j.humimm.2016.07.213.
Conundrum: A negative crossmatch in a patient with high level donor specific antibodyRewinski M, Alberghini T, Bow L, Devivo J, Doyle P, Michalski P, Ortiz-Rivera J. Conundrum: A negative crossmatch in a patient with high level donor specific antibody. Human Immunology 2015, 76: 57. DOI: 10.1016/j.humimm.2015.07.082.
Novel antigen expression of HLA-DR53 in patients with DR7 and DQ9 haplotypeRivera J, Rewinski M, Bow L, DeVivo J, Michalski T, Alberghini T, Doyle P. Novel antigen expression of HLA-DR53 in patients with DR7 and DQ9 haplotype. Human Immunology 2015, 76: 122. DOI: 10.1016/j.humimm.2015.07.171.
Case study: Use of A2 and donor red blood cells for anti ABO a titerMiller M, Bow L. Case study: Use of A2 and donor red blood cells for anti ABO a titer. Human Immunology 2015, 76: 97. DOI: 10.1016/j.humimm.2015.07.141.
Establishing a Next Generation Sequencing laboratory for high resolution HLA typingMcGowan K, Bow L. Establishing a Next Generation Sequencing laboratory for high resolution HLA typing. Human Immunology 2015, 76: 101. DOI: 10.1016/j.humimm.2015.07.146.
Enteric‐coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal‐transplant recipients compared with mycophenolate mofetilFeng J, Zhang L, Zhao P, Bow L, Tian J. Enteric‐coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal‐transplant recipients compared with mycophenolate mofetil. International Journal Of Clinical Practice Supplement 2015, 69: 1-7. PMID: 26176848, DOI: 10.1111/ijcp.12660.
P003 TRANSLATING HLA DATA FROM THE LABORATORY TO THE ELECTRONIC MEDICAL RECORD, THE BUMPY ROAD OF EPIC IMPLEMENTATIONBow L, Maatta J, Rosenthal L, Stavropoulos M, Manley G. P003 TRANSLATING HLA DATA FROM THE LABORATORY TO THE ELECTRONIC MEDICAL RECORD, THE BUMPY ROAD OF EPIC IMPLEMENTATION. Human Immunology 2014, 75: 51. DOI: 10.1016/j.humimm.2014.08.065.
1031-LBP Evaluation of uracil dna glycosylase (UDG) with the LinkSeq™ real-time pcr hla typing methodLizak M, Gerolami K, Bow L. 1031-LBP Evaluation of uracil dna glycosylase (UDG) with the LinkSeq™ real-time pcr hla typing method. Human Immunology 2014, 75: 496. DOI: 10.1016/j.humimm.2014.01.042.
39-P INCREASING MFI CUTOFFS FOR UNACCEPTABLE ANTIGENS INCREASES ACCESS TO ACTUAL DECEASED DONOR CROSSMATCHES FOR THE SENSITIZED RECIPIENTMiller M, Alberghini T, Rewinski M, Bow L. 39-P INCREASING MFI CUTOFFS FOR UNACCEPTABLE ANTIGENS INCREASES ACCESS TO ACTUAL DECEASED DONOR CROSSMATCHES FOR THE SENSITIZED RECIPIENT. Human Immunology 2012, 73: 74. DOI: 10.1016/j.humimm.2012.07.165.
45-P WHEN A DSA IS NOT A DSA: POSITIVE VIRTUAL CROSSMATCHES RESULTING IN ACTUAL NEGATIVE CROSSMATCHESRewinski M, Ortiz J, Bared K, Alberghini T, Bow L. 45-P WHEN A DSA IS NOT A DSA: POSITIVE VIRTUAL CROSSMATCHES RESULTING IN ACTUAL NEGATIVE CROSSMATCHES. Human Immunology 2012, 73: 78. DOI: 10.1016/j.humimm.2012.07.171.
161-P REAL TIME (AND COST) SAVINGS WITH REAL TIME PCR DECEASED DONOR MOLECULAR TYPINGMiller M, Alberghini T, Rewinski M, Bow L. 161-P REAL TIME (AND COST) SAVINGS WITH REAL TIME PCR DECEASED DONOR MOLECULAR TYPING. Human Immunology 2012, 73: 148. DOI: 10.1016/j.humimm.2012.07.287.
56-P Concordance of antibody profile and crossmatch in potential kidney recipientsRewinski M, Miller M, Alberghini T, O'Sullivan D, Bow L, Hull D. 56-P Concordance of antibody profile and crossmatch in potential kidney recipients. Human Immunology 2011, 72: s57. DOI: 10.1016/j.humimm.2011.07.081.
87-P Post-transplant detection of a donor specific (epitope) antibody resulting in a positive flow crossmatchMiller M, Alberghini T, Rewinski M, Bow L. 87-P Post-transplant detection of a donor specific (epitope) antibody resulting in a positive flow crossmatch. Human Immunology 2011, 72: s75. DOI: 10.1016/j.humimm.2011.07.112.
57-P Spin columns eliminate interference in luminex single antigen antibody assayRewinski M, Miller M, Alberghini T, Bow L, Hull D. 57-P Spin columns eliminate interference in luminex single antigen antibody assay. Human Immunology 2011, 72: s57. DOI: 10.1016/j.humimm.2011.07.082.
36-P: Re-Thinking the ROP Trays in Region 1Miller M, Alberghini T, Rewinski M, Michalski T, Bow L. 36-P: Re-Thinking the ROP Trays in Region 1. Human Immunology 2010, 71: s44. DOI: 10.1016/j.humimm.2010.06.084.
37-P: Unacceptble Antigens: How Are They Working?Miller M, Alberghini T, Rewinski M, Michalski T, Bow L. 37-P: Unacceptble Antigens: How Are They Working? Human Immunology 2010, 71: s44. DOI: 10.1016/j.humimm.2010.06.085.
A RETROSPECTIVE ANALYSIS OF THE CLINICAL SIGNIFICANCE OF SOLID PHASE ASSAY (LUMINEX) DETECTION OF PRE-TRANSPLANT HLA ANTIBODY AS MEASURED BY GRAFT OUTCOME IN RENAL TRANSPLANT RECIPIENTSBow L, Miller M, Alberghini T, Hull D, O'Sullivan D, Rewinski M, Lipkowitz G. A RETROSPECTIVE ANALYSIS OF THE CLINICAL SIGNIFICANCE OF SOLID PHASE ASSAY (LUMINEX) DETECTION OF PRE-TRANSPLANT HLA ANTIBODY AS MEASURED BY GRAFT OUTCOME IN RENAL TRANSPLANT RECIPIENTS. Transplantation 2010, 90: 526. DOI: 10.1097/00007890-201007272-00979.
65-P Ashi laboratory survey of post transplant immune monitoring practicesNorin A, Glenn K, Bow L, Pancoska C, Eckels D. 65-P Ashi laboratory survey of post transplant immune monitoring practices. Human Immunology 2006, 67: s99. DOI: 10.1016/j.humimm.2006.08.147.
Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitizationBenedetto B, Lipkowitz G, Madden R, Kurbanov A, Hull D, Miller M, Bow L. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. Journal Of Vascular Surgery 2001, 34: 139-142. PMID: 11436087, DOI: 10.1067/mva.2001.114206.
Response to “A Novel United Network for Organ Sharing Region Kidney Allocation Plan Improves Transplant Access for Minority Candidates”Hull D, Bow L, Mather J. Response to “A Novel United Network for Organ Sharing Region Kidney Allocation Plan Improves Transplant Access for Minority Candidates”. Transplantation 2000, 70: 1113. PMID: 11045655, DOI: 10.1097/00007890-200010150-00024.
Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infectionOnyeji C, Nicolau D, Nightingale C, Bow L. Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. Journal Of Antimicrobial Chemotherapy 2000, 46: 429-436. PMID: 10980170, DOI: 10.1093/jac/46.3.429.
Influence of adjunctive interferon-γ on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in miceOnyeji C, Bui K, Nicolau D, Nightingale C, Bow L, Quintiliani R. Influence of adjunctive interferon-γ on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice. International Journal Of Antimicrobial Agents 1999, 12: 301-309. PMID: 10493606, DOI: 10.1016/s0924-8579(99)00055-2.
A NOVEL UNOS REGION KIDNEY ALLOCATION PLAN IMPROVES TRANSPLANT ACCESS FOR MINORITY CANDIDATESDelmonico F, Milford E, Goguen J, Harmon W, Bow L, Lipkowitz G, Himmelfarb J, Mah H, Fan P, Rohrer R, Lorber M. A NOVEL UNOS REGION KIDNEY ALLOCATION PLAN IMPROVES TRANSPLANT ACCESS FOR MINORITY CANDIDATES. Transplantation 1999, 67: s143. DOI: 10.1097/00007890-199904150-00576.
A new allocation plan for renal transplantationDelmonico F, Harmon W, Lorber M, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Bow L, Milford E, Rohrer R. A new allocation plan for renal transplantation. Transplantation Proceedings 1999, 31: 358-359. PMID: 10083141, DOI: 10.1016/s0041-1345(98)01660-1.
A NEW ALLOCATION PLAN FOR RENAL TRANSPLANTATION1Delmonico F, Harmon W, Lorber M, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Bow L, Milford E, Rohrer R. A NEW ALLOCATION PLAN FOR RENAL TRANSPLANTATION1. Transplantation 1999, 67: 303-309. PMID: 10075599, DOI: 10.1097/00007890-199901270-00021.
Interferon-γ effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophilsOnyeji C, Nicolau D, Nightingale C, Bow L. Interferon-γ effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils. International Journal Of Antimicrobial Agents 1999, 11: 31-37. PMID: 10075275, DOI: 10.1016/s0924-8579(98)00085-5.
In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G.Xuan D, Nicolau D, Tessier P, Bow L, Quintiliani R, Nightingale C. In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G. Antimicrobial Agents And Chemotherapy 1997, 41: 1512-1516. PMID: 9210676, PMCID: PMC163950, DOI: 10.1128/aac.41.7.1512.
Localized delivery of heparin to angioplasty sites with iontophoresisMitchel J, Azrin M, Fram D, Bow L, McKay R. Localized delivery of heparin to angioplasty sites with iontophoresis. Catheterization And Cardiovascular Interventions 1997, 41: 315-323. PMID: 9213031, DOI: 10.1002/(sici)1097-0304(199707)41:3<315::aid-ccd13>3.0.co;2-m.
Local delivery of c‐myb antisense oligonucleotides during balloon angioplastyAzrin M, Mitchel J, Bow L, Pedersen C, Cartun R, Aretz T, Waters D, McKay R. Local delivery of c‐myb antisense oligonucleotides during balloon angioplasty. Catheterization And Cardiovascular Interventions 1997, 41: 232-240. PMID: 9213020, DOI: 10.1002/(sici)1097-0304(199707)41:3<232::aid-ccd2>3.0.co;2-7.
Local urokinase delivery with the Channel balloon: Device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysisMitchel J, Barry J, Bow L, Alberghini T, Abbas S, McKay R. Local urokinase delivery with the Channel balloon: Device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis. Catheterization And Cardiovascular Interventions 1997, 41: 254-260. PMID: 9213023, DOI: 10.1002/(sici)1097-0304(199707)41:3<254::aid-ccd5>3.0.co;2-5.
Functional and structural alterations with 24-hour myocardial hibernation and recovery after reperfusion. A pig model of myocardial hibernation.Chen C, Chen L, Fallon J, Ma L, Li L, Bow L, Knibbs D, McKay R, Gillam L, Waters D. Functional and structural alterations with 24-hour myocardial hibernation and recovery after reperfusion. A pig model of myocardial hibernation. Circulation 1996, 94: 507-16. PMID: 8759096, DOI: 10.1161/01.cir.94.3.507.
Organ transplantation at the Hartford Transplant Center.Schweizer R, Bartus S, Hull D, Perdrizet G, Swanson M, Low H, Gallagher R, Dougherty J, Rosson R, Hyams J, D'Avella J, Rasoulpour M, Sullivan P, Bow L. Organ transplantation at the Hartford Transplant Center. Connecticut Medicine 1996, 60: 387-93. PMID: 8758656.
Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare.Onyeji C, Nightingale C, Tessier P, Nicolau D, Bow L. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. The Journal Of Infectious Diseases 1995, 172: 810-6. PMID: 7658075, DOI: 10.1093/infdis/172.3.810.
Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies.Mitchel J, Fram D, Palme D, Foster R, Hirst J, Azrin M, Bow L, Eldin A, Waters D, McKay R. Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies. Circulation 1995, 91: 785-93. PMID: 7828307, DOI: 10.1161/01.cir.91.3.785.
1001–23 Localized Intracoronary Delivery of Urokinase with the Channelled Balloon: Pharmacokinetics of Drug Delivery and WashoutMitchel J, Fram D, Azrin M, Bow L, Alberghini T, Eldin A, Shwedick M, Waters D, McKay R. 1001–23 Localized Intracoronary Delivery of Urokinase with the Channelled Balloon: Pharmacokinetics of Drug Delivery and Washout. Journal Of The American College Of Cardiology 1995, 25: 347a. DOI: 10.1016/0735-1097(95)92897-e.
1001–24 Local Delivery of Urokinase to Porcine Coronary Arteries Using the Localmed Infusion SleeveAzrin M, Mitchel J, Bow L, Alberghini T, Grant G, Kaplan A, Waters D, McKay R. 1001–24 Local Delivery of Urokinase to Porcine Coronary Arteries Using the Localmed Infusion Sleeve. Journal Of The American College Of Cardiology 1995, 25: 347a. DOI: 10.1016/0735-1097(95)92898-f.
Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.Mitchel J, Azrin M, Fram D, Hong M, Wong S, Barry J, Bow L, Curley T, Kiernan F, Waters D. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 1994, 90: 1979-1988. PMID: 7923688, DOI: 10.1161/01.cir.90.4.1979.
Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons.Azrin M, Mitchel J, Fram D, Pedersen C, Cartun R, Barry J, Bow L, Waters D, McKay R. Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation 1994, 90: 433-441. PMID: 8026030, DOI: 10.1161/01.cir.90.1.433.
Causes of late graft failure in cadaveric renal transplantation.Bergmann L, Roper L, Bow L, Hull D, Bartus S, Schweizer R. Causes of late graft failure in cadaveric renal transplantation. Transplantation Proceedings 1993, 25: 1340-1. PMID: 8442136.
Late graft loss in cadaveric renal transplantation.Bergmann L, Roper L, Bow L, Hull D, Bartus S, Schweizer R. Late graft loss in cadaveric renal transplantation. Transplantation Proceedings 1992, 24: 2718-9. PMID: 1465913.
Cytotoxic antibody formation following nonimmunologic loss of kidney transplantsMichalski P, Bow L, Roper L, Schweizer R. Cytotoxic antibody formation following nonimmunologic loss of kidney transplants. Human Immunology 1992, 34: 75. DOI: 10.1016/0198-8859(92)90253-j.
Discrimination of the SLA CC and DD haplotype of mini-swine by polymerase chain reactionBow L, Alberghini T, Bergmann L, Schweizer R. Discrimination of the SLA CC and DD haplotype of mini-swine by polymerase chain reaction. Human Immunology 1992, 34: 106. DOI: 10.1016/0198-8859(92)90315-e.
Transplantation of cadaver kidneys from pediatric and older donors.Bow L, Roper L, Bartus S, Hull D, Schweizer R. Transplantation of cadaver kidneys from pediatric and older donors. Transplantation Proceedings 1989, 21: 1938-9. PMID: 2652632.
DRw6 (DRw13, DRw14): 2-D Gel PatternsCharron D, Hermans P, Ballas M, Brahmi Z, du Toit E, Martell R, Bow L, Bontrop R. DRw6 (DRw13, DRw14): 2-D Gel Patterns. 1989, 393-395. DOI: 10.1007/978-1-4612-3552-1_85.
DRw52: 2-D Gel PatternsBontrop R, Ballas M, Madrigal A, Hermans P, Fuggle S, Otting Ń, Carter C, Sacks S, Kaplan C, Morel M, Radka S, Nepom B, Bow L, Du Toit E, Crawford S, Knitter-Jack N, Nepom G, Mazzilli M, Brahmi Z, Charron D. DRw52: 2-D Gel Patterns. 1989, 401-404. DOI: 10.1007/978-1-4612-3552-1_89.
DQw1 (DQw5, DQw6): 2-D Gel PatternsKaplan C, Morel M, Hermans P, Tkaczuk J, Naskatsuji T, Fernandez N, Rust N, Carter C, Fuggle S, Dejelo C, Marshall W, Wong K, Ballas M, Brahmi Z, Du Toit E, Martell R, Bow L, Kulova L, Winchester R, Bontrop R, Charron D. DQw1 (DQw5, DQw6): 2-D Gel Patterns. 1989, 407-410. DOI: 10.1007/978-1-4612-3552-1_91.
5.1-01 Comparison of flow cytometry (FC) and antiglobulin (AHG) augmented cytotoxicity crossmatchingReynolds B, Michalski P, Krisiunas L, Schweizer R, Bow L. 5.1-01 Comparison of flow cytometry (FC) and antiglobulin (AHG) augmented cytotoxicity crossmatching. Human Immunology 1989, 26: 35. DOI: 10.1016/0198-8859(89)90660-5.
5.1-02 Experience with dithiothreitol crossmatching in a highly sensitized populationDwyer D, Michalski P, Schweizer R, Krisiunas L, Bow L. 5.1-02 Experience with dithiothreitol crossmatching in a highly sensitized population. Human Immunology 1989, 26: 36. DOI: 10.1016/0198-8859(89)90661-7.
Renal transplantation at Hartford Hospital: results of combined and flexible immunosuppression.Schweizer R, Bow L, Roper L, Hull D, Bartus S. Renal transplantation at Hartford Hospital: results of combined and flexible immunosuppression. Clinical Transplants 1988, 147-58. PMID: 3154467.
Importance of cold reacting anti-RBC autoagglutins in renal transplantationSchweizer R, Reynolds B, Pfau P, Bow L. Importance of cold reacting anti-RBC autoagglutins in renal transplantation. Human Immunology 1988, 23: 144. DOI: 10.1016/0198-8859(88)90256-x.
USE OF TWO DONOR-SPECIFIC TRANSFUSIONS FOR LIVING -RELATED DONOR KIDNEY TRANSPLANTATIONSchweizer R, Bartus S, Rovelli M, Bow L. USE OF TWO DONOR-SPECIFIC TRANSFUSIONS FOR LIVING -RELATED DONOR KIDNEY TRANSPLANTATION. Transplantation 1986, 42: 564-567. PMID: 3538543, DOI: 10.1097/00007890-198611000-00026.
Neonatal tolerance increases efficacy of antisera productionSharpe R, Schweizer R, Bow L. Neonatal tolerance increases efficacy of antisera production. Medical Hypotheses 1985, 17: 265-270. PMID: 3876502, DOI: 10.1016/0306-9877(85)90132-x.
EVIDENCE THAT CYCLOSPORINE-INCUBATED PLATELETS RETAIN FUNCTION AND RELEASE CYCLOSPORINESharpe R, Schweizer R, Moore R, Calaluce R, Johnson R, Michalski P, Bow L. EVIDENCE THAT CYCLOSPORINE-INCUBATED PLATELETS RETAIN FUNCTION AND RELEASE CYCLOSPORINE. Transplantation 1985, 40: 102-105. PMID: 4012843, DOI: 10.1097/00007890-198507000-00021.
Serologic considerations in donor-specific transfusion therapy for kidney transplantation.Schweizer R, Bow L, Generas D, Bartus S. Serologic considerations in donor-specific transfusion therapy for kidney transplantation. Transplantation Proceedings 1982, 14: 374-7. PMID: 6810522.
Beta 2-microglobulin monitoring after renal transplantation.Schweizer R, Moore R, Bartus S, Bow L, Hayden J. Beta 2-microglobulin monitoring after renal transplantation. Transplantation Proceedings 1981, 13: 1620-3. PMID: 6171078.
Successful kidney transplantation despite T lymphocyte cytotoxicity: Role of donor specific blood transfusionSchweizer R, Bow L, Hosey D, Bartus S. Successful kidney transplantation despite T lymphocyte cytotoxicity: Role of donor specific blood transfusion. Human Immunology 1980, 1: 283-284. DOI: 10.1016/0198-8859(80)90078-6.

Edit Profile

Contact Information

Research & Publications

Biography

Coauthors

Selected Publications